Clinical Trial Search

Primary: Proportion of Subjects Reporting AEs of Chronic Lower Abdominal and/or Pelvic Pain After Insertion of Essure System or After Laparoscopic Tubal Sterilization — 39; 28…

Primary: Mean Difference Between Pre and Postoperative Hemoglobin (g/dl) — 1.4; 1.8 g/dL — p=0.08

Primary: Number of Occluded Fallopian Tubes 60 Minutes After Placement of the Insert as Measured by an HSG Evaluation — 36; NA; NA; NA Occluded fallopian tubes

Primary: To Determine if the LigaSure Device, Which we Routinely Used for Removal of Tubes and Ovaries, is Effective at Destroying All Tubal Cells Comprising the Fallopian Tube…

Primary: Number of Participants With Bilateral Tubal Patency as Assessed by HSG-follicular — 9; 1 Participants — p=0.4795

Primary: Intrauterine Fluid Volume Lost — 2.2; 7.8 ml

Primary: Change in Patient-perceived Pain Between Baseline and Cannulization — 29.5; 35 score on a scale

Primary: Vulvovaginal Symptoms Questionnaire — 8; 7.88; 5.93; 5.93 score on a scale

Primary: Success (Reduction in Menstruation to Normal Levels) — 59 Participants — p=.271

Primary: Concordance Between Cytological Findings From Fallopian Tubes to Surgical Histology Results. — 42; 2 fallopian tubes

Primary: The Primary Outcome is LNG-IUD Usage Six Months Following Enrollment. — 85.2; 62.9 percentage of participants — p=0.05

Primary: Change of Stamey Grade From Baseline to 12 Months. — -1.17 units on a scale — p=<0.001

Primary: 6 Month Pregnancy Probabilities With Typical Use — 0.5; 1.4; 4.0 percentage of probability

Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221

Primary: Change From Baseline in Pain Scale Measurement During and After the Procedure — 1.1; 2.5; 15.6; 15.4 units on a scale

Primary: Patient-perceived Pain — 3; 4 score on a scale — p=0.21

Primary: Effect of RF on Pelvic Floor Measured by Intentional Muscle Contraction Using Biofeedback EMS — 13.13 mV

Primary: Number of Participants With Pregnancy in Loop-shaped Intrauterine Device Group and Intrauterine Balloon Group — 12; 22 participants — p=0.009

Primary: Cell Proliferation in the Fallopian Tube Fimbriae as Measured by Ki-67%+ — 8.3 percentage of positively stained cells

Primary: Contraceptive Method Discontinuation — 300; 62; 142 Participants

Primary: Changes From Baseline in the Post Coital Test Results (PCT) Due to Device Use. — 0; 26 Participants

Primary: Number of Participants With Absence of Newly Formed Intrauterine Adhesions Following RF Ablation of Fibroids — 34 Participants

Primary: Post-operative Evidence of Adenomyoma Tissue Ablation Effect by Area (n) as Assessed by Pathological Analysis — 9; 8; 7; 6 treated areas

Primary: Mean Number of Bleeding or Spotting Days — 16; 28 days

Primary: Patient Satisfaction — 4.92; 4.84 units on a scale — p=0.57

Primary: Percentage of Subjects With ≥ 50% Reduction in Menstrual Blood Loss as Assessed by Pictorial Blood Loss Assessment Chart (PBAC) — 64.8 percentage of participants

Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants

Primary: Assessment of Menstrual Blood Flow (MBF) at 12 Months Post Procedure — 40.2; 48.8; 59.1; 67.7 Percentage of participants

Primary: Procedure Time — 22.4; 22.6 minutes

Primary: The Primary Endpoint of This Study is Time Difference Between Cauterizing One Side of the Uterine Attachments, From the Round Ligament to the Uterine Artery on One Side…